1193 related articles for article (PubMed ID: 23559588)
21. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
[TBL] [Abstract][Full Text] [Related]
22. PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?
Chiaravalloti A; Di Biagio D; Tavolozza M; Calabria F; Schillaci O
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1418-24. PubMed ID: 26791373
[TBL] [Abstract][Full Text] [Related]
23. Prospective, Multisite, International Comparison of
Emmett L; Metser U; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Punwani S; Pond G; Chua S; Ho B; Johnston E; Pouliot F; Scott AM
J Nucl Med; 2019 Jun; 60(6):794-800. PubMed ID: 30442757
[TBL] [Abstract][Full Text] [Related]
24. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
Mol Imaging Biol; 2010; 12(1):98-107. PubMed ID: 19588206
[TBL] [Abstract][Full Text] [Related]
25. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.
Cimitan M; Bortolus R; Morassut S; Canzonieri V; Garbeglio A; Baresic T; Borsatti E; Drigo A; Trovò MG
Eur J Nucl Med Mol Imaging; 2006 Dec; 33(12):1387-98. PubMed ID: 16865395
[TBL] [Abstract][Full Text] [Related]
26. Metastatic prostate cancer proven by 18F-FCH PET/CT staging scan in patient with normal PSA but high PSA doubling time.
Hodolič M; Maffione AM; Fettich J; Gubina B; Cimitan M; Rubello D
Clin Nucl Med; 2013 Sep; 38(9):739-40. PubMed ID: 23816948
[TBL] [Abstract][Full Text] [Related]
27. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
Ceci F; Castellucci P; Mamede M; Schiavina R; Rubello D; Fuccio C; Ambrosini V; Boschi S; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):149-55. PubMed ID: 23151910
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?
Calabria F; Chiaravalloti A; Tavolozza M; Ragano-Caracciolo C; Schillaci O
Nucl Med Commun; 2013 Aug; 34(8):733-40. PubMed ID: 23680652
[TBL] [Abstract][Full Text] [Related]
29. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
Ceci F; Castellucci P; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Ntreta M; Lodi F; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):878-86. PubMed ID: 24346416
[TBL] [Abstract][Full Text] [Related]
30. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
Mol Imaging Biol; 2009; 11(6):446-54. PubMed ID: 19326171
[TBL] [Abstract][Full Text] [Related]
31. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates.
Krause BJ; Souvatzoglou M; Treiber U
Urol Oncol; 2013 May; 31(4):427-35. PubMed ID: 21388835
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer.
Husarik DB; Miralbell R; Dubs M; John H; Giger OT; Gelet A; Cservenyàk T; Hany TF
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):253-63. PubMed ID: 17926036
[TBL] [Abstract][Full Text] [Related]
33. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
Poulsen MH; Petersen H; Høilund-Carlsen PF; Jakobsen JS; Gerke O; Karstoft J; Steffansen SI; Walter S
BJU Int; 2014 Dec; 114(6):818-23. PubMed ID: 24314065
[TBL] [Abstract][Full Text] [Related]
34. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
Simone G; Di Pierro GB; Papalia R; Sciuto R; Rea S; Ferriero M; Guaglianone S; Maini CL; Gallucci M
World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130
[TBL] [Abstract][Full Text] [Related]
35. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
36. Role of PET-CT with
Puche-Sanz I; Triviño-Ibáñez E; Vázquez-Alonso F; Llamas-Elvira JM; Cózar-Olmo JM; Rodríguez-Fernández A
Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
[TBL] [Abstract][Full Text] [Related]
37. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
38. BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study).
Beheshti M; Kunit T; Haim S; Zakavi R; Schiller C; Stephens A; Dinkelborg L; Langsteger W; Loidl W
Mol Imaging Biol; 2015 Jun; 17(3):424-33. PubMed ID: 25315836
[TBL] [Abstract][Full Text] [Related]
39. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
[TBL] [Abstract][Full Text] [Related]
40. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study.
Fuccio C; Schiavina R; Castellucci P; Rubello D; Martorana G; Celli M; Malizia C; Profitos MB; Marzola MC; Pettinato V; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1985-9. PubMed ID: 21732105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
